Long-term Survival and Excellent Response to Repeated 177Lu–Prostate-Specific Membrane Antigen 617 Radioligand Therapy in a Patient With Advanced Metastatic Castration-Resistant Prostate Cancer. (October 2018)

• Record Type: Journal Article
• Authors: Roll, Wolfgang; Bräuer, Axel; Weckesser, Matthias; Bögemann, Martin; Rahbar, Kambiz
• Is Part Of: Clinical nuclear medicine. Volume 43:Number 10(2018)
• Publication Date: 2018-10
• Subjects: 177Lu-PSMA therapy -- mCRPC -- PSMA PET/CT -- RLT; Nuclear medicine -- Periodicals; Radioisotope scanning -- Periodicals; Nuclear Medicine -- Periodicals; 616.07575
• DOI: 10.1097/RLU.0000000000002212
• Languages: English
• ISSNs: 0363-9762

Abstract

Abstract : Abstract: Radiolabeled ligands targeting prostate-specific membrane antigen (PSMA) are currently being established. Prostate-specific membrane antigen radioligand therapy with 177 Lu-PSMA-617 is a promising treatment in metastasized castration-resistant prostate cancer with high efficacy and safety and seems to prolong progression-free survival and overall survival. We present 68 Ga-PSMA PET/CT images during and after 2 therapy courses, including each 4 cycles of 177 Lu-PSMA-617, and prostate-specific antigen–level history of a 77-year-old heavily pretreated patient with metastasized castration-resistant prostate cancer.